Announcements Trials
Browse Landscape

Status

No longer available 1Available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 471Observational 38Expanded_access 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Non-Small-Cell Lung 14Neoplasms 11Multiple Myeloma 10Recurrence 9Pancreatic Neoplasms 8Prostatic Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Ovarian Neoplasms 6Neuroblastoma 6Melanoma 6Leukemia, Myeloid, Acute 6Sarcoma 5Hematologic Neoplasms 4Glioblastoma 4Breast Neoplasms 4Stomach Neoplasms 3Osteosarcoma 3Non-Muscle Invasive Bladder Neoplasms 3Neuroectodermal Tumors, Primitive 3Myelodysplastic Syndromes 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Lung Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Carcinoma, Squamous Cell 3Uterine Neoplasms 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2

Interventions

leronlimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × Triple Negative Breast Neoplasms × 1 year × Clear all
NCT07536815 2026-04-27

An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)

CytoDyn, Inc.

Available
Breast

Triple Negative Breast Neoplasms

NCT04313075 2025-07-15

A Compassionate Use Study of Leronlimab in Breast Cancer

CytoDyn, Inc.

No longer available
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡